Zhenzhen Jiang Selected Research

Esophageal Squamous Cell Carcinoma

5/2021	CYP2C9 inhibits the invasion and migration of esophageal squamous cell carcinoma via downregulation of HDAC.
1/2021	Identification and Functional Validation of Radioresistance-Related Genes AHNAK2 and EVPL in Esophageal Squamous Cell Carcinoma by Exome and Transcriptome Sequencing Analyses.
1/2020	NVP-BSK805, an Inhibitor of JAK2 Kinase, Significantly Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma in vitro and in vivo.
7/2019	Single-cell RNA-seq of esophageal squamous cell carcinoma cell line with fractionated irradiation reveals radioresistant gene expression patterns.
1/2019	Cancer-associated Fibroblast-promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma.
1/2017	CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma.
7/2016	Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma.
3/2015	Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhenzhen Jiang Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 07/2016
8	Esophageal Squamous Cell Carcinoma 05/2021 - 03/2015
3	Inflammation (Inflammations) 12/2020 - 01/2016
2	Hypertrophy 01/2016 - 08/2015
1	Testicular Germ Cell Tumor 01/2022
1	Calculi (Calculus) 05/2021
1	Adenocarcinoma of Lung 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Hypoxia (Hypoxemia) 01/2019
1	Esophageal Neoplasms (Esophageal Cancer) 01/2019
1	Necrosis 07/2018
1	Edema (Dropsy) 07/2018
1	Traumatic Brain Injuries (Traumatic Brain Injury) 07/2018
1	Renal Hypertension 01/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Proteinuria 01/2016
1	Cardio-Renal Syndrome 01/2016
1	Hypertension (High Blood Pressure) 01/2016
1	Chronic Renal Insufficiency 01/2016

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2016
2	Long Noncoding RNAIBA 01/2022 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 07/2018
2	CytokinesIBA 07/2018 - 01/2016
1	Untranslated RNA (Noncoding RNA)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	pien tze huangIBA 05/2021
1	CarcinogensIBA 05/2021
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 05/2021
1	Cytochrome P-450 CYP2C9IBA 05/2021
1	NF-kappa B (NF-kB)IBA 12/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	NVP-BSK805IBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Radiation-Sensitizing AgentsIBA 01/2020
1	Caspase 3 (Caspase-3)IBA 01/2020
1	Caspase 8 (Caspase-8)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 07/2019
1	Dexmedetomidine FDA Link 01/2019
1	MB 3 (MB-3)IBA 01/2019
1	HMGB1 Protein (HMG1)IBA 01/2019
1	Therapeutic UsesIBA 07/2018
1	NADP (NADPH)IBA 01/2016
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2016
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2016
1	renalaseIBA 01/2016
1	MicroRNAs (MicroRNA)IBA 08/2015
1	Small Interfering RNA (siRNA)IBA 08/2015
1	Glucose (Dextrose)FDA LinkGeneric 08/2015

Therapy/Procedure

5	Radiotherapy 01/2021 - 03/2015
2	Chemoradiotherapy 01/2017 - 01/2017
1	Immunotherapy 01/2022
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 05/2021
1	Aftercare (After-Treatment) 01/2020
1	Intravenous Infusions 07/2018
1	Therapeutics 07/2016
1	Nephrectomy 01/2016